Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Prediabetes / Type 2 Diabetes
Interventions
DRUG

Metformin

16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.

DRUG

GLP-1A

16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.

DIETARY_SUPPLEMENT

MED

16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT06682351 - Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention | Biotech Hunter | Biotech Hunter